PortfoliosLab logo
PortfoliosLab logo
Tools
Performance Analysis
Portfolio Analysis
Factor Model
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
GTBP vs. NFLY
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility

Correlation

The correlation between GTBP and NFLY is 0.05, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.


-0.50.00.51.00.0

Performance

GTBP vs. NFLY - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in GT Biopharma, Inc. (GTBP) and YieldMax NFLX Option Income Strategy ETF (NFLY). The values are adjusted to include any dividend payments, if applicable.

-20.00%0.00%20.00%40.00%60.00%SeptemberOctoberNovemberDecember2025February
-1.90%
42.02%
GTBP
NFLY

Key characteristics

Sharpe Ratio

GTBP:

-0.24

NFLY:

2.80

Sortino Ratio

GTBP:

0.79

NFLY:

3.63

Omega Ratio

GTBP:

1.09

NFLY:

1.52

Calmar Ratio

GTBP:

-0.44

NFLY:

6.51

Martin Ratio

GTBP:

-0.75

NFLY:

20.07

Ulcer Index

GTBP:

58.45%

NFLY:

3.23%

Daily Std Dev

GTBP:

185.34%

NFLY:

23.30%

Max Drawdown

GTBP:

-99.95%

NFLY:

-21.45%

Current Drawdown

GTBP:

-99.94%

NFLY:

-1.37%

Returns By Period

In the year-to-date period, GTBP achieves a -31.15% return, which is significantly lower than NFLY's 12.32% return.


GTBP

YTD

-31.15%

1M

-12.13%

6M

-1.87%

1Y

-50.82%

5Y*

-47.19%

10Y*

N/A

NFLY

YTD

12.32%

1M

15.40%

6M

42.02%

1Y

64.18%

5Y*

N/A

10Y*

N/A

*Annualized

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Risk-Adjusted Performance

GTBP vs. NFLY — Risk-Adjusted Performance Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

GTBP
The Risk-Adjusted Performance Rank of GTBP is 3636
Overall Rank
The Sharpe Ratio Rank of GTBP is 3232
Sharpe Ratio Rank
The Sortino Ratio Rank of GTBP is 5252
Sortino Ratio Rank
The Omega Ratio Rank of GTBP is 4949
Omega Ratio Rank
The Calmar Ratio Rank of GTBP is 2020
Calmar Ratio Rank
The Martin Ratio Rank of GTBP is 2828
Martin Ratio Rank

NFLY
The Risk-Adjusted Performance Rank of NFLY is 9494
Overall Rank
The Sharpe Ratio Rank of NFLY is 9595
Sharpe Ratio Rank
The Sortino Ratio Rank of NFLY is 9393
Sortino Ratio Rank
The Omega Ratio Rank of NFLY is 9393
Omega Ratio Rank
The Calmar Ratio Rank of NFLY is 9797
Calmar Ratio Rank
The Martin Ratio Rank of NFLY is 9494
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

GTBP vs. NFLY - Risk-Adjusted Performance Comparison

This table presents a comparison of risk-adjusted performance metrics for GT Biopharma, Inc. (GTBP) and YieldMax NFLX Option Income Strategy ETF (NFLY). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


Sharpe ratio
The chart of Sharpe ratio for GTBP, currently valued at -0.24, compared to the broader market-2.000.002.004.00-0.242.80
The chart of Sortino ratio for GTBP, currently valued at 0.79, compared to the broader market-6.00-4.00-2.000.002.004.006.000.793.63
The chart of Omega ratio for GTBP, currently valued at 1.09, compared to the broader market0.501.001.502.001.091.52
The chart of Calmar ratio for GTBP, currently valued at -0.54, compared to the broader market0.002.004.006.00-0.546.51
The chart of Martin ratio for GTBP, currently valued at -0.75, compared to the broader market0.0010.0020.0030.00-0.7520.07
GTBP
NFLY

The current GTBP Sharpe Ratio is -0.24, which is lower than the NFLY Sharpe Ratio of 2.80. The chart below compares the historical Sharpe Ratios of GTBP and NFLY, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.


Rolling 12-month Sharpe Ratio0.001.002.003.00SeptemberOctoberNovemberDecember2025February
-0.24
2.80
GTBP
NFLY

Dividends

GTBP vs. NFLY - Dividend Comparison

GTBP has not paid dividends to shareholders, while NFLY's dividend yield for the trailing twelve months is around 46.47%.


TTM20242023
GTBP
GT Biopharma, Inc.
0.00%0.00%0.00%
NFLY
YieldMax NFLX Option Income Strategy ETF
46.47%49.91%11.84%

Drawdowns

GTBP vs. NFLY - Drawdown Comparison

The maximum GTBP drawdown since its inception was -99.95%, which is greater than NFLY's maximum drawdown of -21.45%. Use the drawdown chart below to compare losses from any high point for GTBP and NFLY. For additional features, visit the drawdowns tool.


-80.00%-60.00%-40.00%-20.00%0.00%SeptemberOctoberNovemberDecember2025February
-77.92%
-1.37%
GTBP
NFLY

Volatility

GTBP vs. NFLY - Volatility Comparison

GT Biopharma, Inc. (GTBP) has a higher volatility of 22.98% compared to YieldMax NFLX Option Income Strategy ETF (NFLY) at 6.93%. This indicates that GTBP's price experiences larger fluctuations and is considered to be riskier than NFLY based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


0.00%10.00%20.00%30.00%40.00%50.00%60.00%SeptemberOctoberNovemberDecember2025February
22.98%
6.93%
GTBP
NFLY
PortfoliosLab logo
Performance Analysis
Portfolio AnalysisPortfolio PerformanceStock ComparisonSharpe RatioMartin RatioTreynor RatioSortino RatioOmega RatioCalmar RatioSummers Ratio
Community
Discussions


Disclaimer

The information contained herein does not constitute investment advice and made available for educational purposes only. Prices and returns on equities are listed without consideration of fees, commissions, taxes, penalties, or interest payable due to purchasing, holding, or selling.

Copyright © 2025 PortfoliosLab